Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

141. Relationship between occult hepatitis B virus infection and chronic kidney disease in a Chinese population-based cohort Full Text available with Trip Pro

Relationship between occult hepatitis B virus infection and chronic kidney disease in a Chinese population-based cohort Previous studies have revealed inconsistent results regarding the association between occult hepatitis B virus (HBV) infection and chronic kidney disease (CKD). Therefore, we conducted a prospective cohort study to evaluate the association between occult HBV infection and CKD.A total of 4329 adults, aged 46.2 ± 13.7 years, without CKD at baseline were enrolled while undergoing (...) physical examinations. Occult HBV infection was defined as seropositivity for antibody to HBV core antigen. CKD was defined as decreased estimated glomerular filtration rate (eGFR < 60 ml·min-1·1.73 m-2) or presence of proteinuria ≥1+, assessed using a repeated dipstick method. eGFR was computed using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.The prevalence of occult HBV infection was 8.1% (352/4329). During 5 years of follow-up, 165 patients (3.8%) developed CKD

2016 Chronic diseases and translational medicine

142. Trends in Prevalence of Chronic Kidney Disease in the United States. Full Text available with Trip Pro

Trends in Prevalence of Chronic Kidney Disease in the United States. Trends in the prevalence of chronic kidney disease (CKD) are important for health care policy and planning.To update trends in CKD prevalence.Repeated cross-sectional study.NHANES (National Health and Nutrition Examination Survey) for 1988 to 1994 and every 2 years from 1999 to 2012.Adults aged 20 years or older.Chronic kidney disease (stages 3 and 4) was defined as an estimated glomerular filtration rate (eGFR) of 15 to 59 mL (...) /min/1.73 m2, estimated with the Chronic Kidney Disease Epidemiology Collaboration equation from calibrated serum creatinine measurements. An expanded definition of CKD also included persons with an eGFR of at least 60 mL/min/1.73 m2 and a 1-time urine albumin-creatinine ratio of at least 30 mg/g.The unadjusted prevalence of stage 3 and 4 CKD increased from the late 1990s to the early 2000s. Since 2003 to 2004, however, the overall prevalence has largely stabilized (for example, 6.9% prevalence

2016 Annals of Internal Medicine

143. Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study Full Text available with Trip Pro

Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study Levels of fibroblast growth factor 23 (FGF23) are elevated in chronic kidney disease (CKD) and strongly associated with left ventricular hypertrophy, heart failure, and death. Whether FGF23 is an independent risk factor for atrial fibrillation in CKD is unknown.To investigate the association of FGF23 with atrial fibrillation in CKD.Prospective cohort (...) study of 3876 individuals with mild to severe CKD who enrolled in the Chronic Renal Insufficiency Cohort Study between June 19, 2003, and September 3, 2008, and were followed up through March 31, 2013.Baseline plasma FGF23 levels.Prevalent and incident atrial fibrillation.The study cohort comprised 3876 participants. Their mean (SD) age was 57.7 (11.0) years, and 44.8% (1736 of 3876) were female. Elevated FGF23 levels were independently associated with increased odds of prevalent atrial fibrillation

2016 JAMA cardiology

144. Implantation of Autologous Selected Renal Cells in Diabetic Chronic Kidney Disease Stages 3 and 4—Clinical Experience of a “First in Human” Study Full Text available with Trip Pro

Implantation of Autologous Selected Renal Cells in Diabetic Chronic Kidney Disease Stages 3 and 4—Clinical Experience of a “First in Human” Study Animal models of chronic kidney disease demonstrate that a redundant population of therapeutically bioactive selected renal cells (SRCs) can be delivered to the kidney through intraparenchymal injection and arrest disease progression. Direct injection of SRCs has been shown to attenuate nuclear factor-κB, which is known to drive tissue (...) inflammation, as well as the transforming growth factor-β-mediated plasminogen activator inhibitor-1 response that drives tissue fibrosis.We present experience from the first-in-human clinical study with SRCs. Seven male type 2 diabetic patients (63 ± 2 years of age) with chronic kidney disease stage 3 to 4 (estimated glomerular filtration rate 25 ± 2 ml/min) were recruited. After blood and urine sampling, iohexol clearance, magnetic resonance imaging, and renal scintigraphy, patients underwent ultrasound

2016 Kidney international reports

145. Grape seed powder improves renal failure of chronic kidney disease patients Full Text available with Trip Pro

Grape seed powder improves renal failure of chronic kidney disease patients Chronic kidney disease (CKD) is a syndrome characterized by progressive and irreversible deterioration of renal function linked to slow destruction of renal parenchyma, eventually terminating in death when sufficient number of nephrons are damaged. Oxidative stress is commonly observed in CKD patients resulting from an imbalance between overproduction of reactive oxygen species (ROS) and impairment of defence mechanisms (...) . Grape seed extract (GSE) is a polyphenolic mixture exhibiting antioxidant and anti-inflammatory properties. We conducted an interventional pilot study of supplementation with GSE capsules (GSE group, n = 23) or placebo (control group, n = 10) on CKD patients. Blood and urine samples were collected at baseline and after a six-month-long supplementation period to determine some renal function biomarkers, as well as antioxidant, anti-inflammatory and haematological parameters. GSE improved glomerular

2016 EXCLI journal Controlled trial quality: uncertain

146. Ambulatory Blood Pressure in Chronic Kidney Disease: Ready for Prime Time? Full Text available with Trip Pro

Ambulatory Blood Pressure in Chronic Kidney Disease: Ready for Prime Time? Hypertension is common in patients with chronic kidney disease (CKD) and is the most important modifiable risk factor for CKD progression and adverse cardiovascular events in these patients. Diagnosis and successful management of hypertension are critically dependent on accurate blood pressure (BP) measurement. This is most relevant to CKD patients, in whom BP control is difficult to achieve and in whom early (...) antihypertensive treatment is imperative to prevent kidney and cardiovascular complications. Accumulated data indicate that ambulatory blood pressure monitoring (ABPM) is better in detecting hypertension than office BP measurement. ABPM is also a superior prognostic marker compared with office BP and has successfully identified hypertensive CKD patients at increased risk. Additionally, ABPM provides information on circadian BP variation and short-term BP variability, which is associated with cardiovascular

2016 Kidney international reports

147. Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease. Full Text available with Trip Pro

Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease. Patients with chronic kidney disease (CKD) are at an increased risk of cardiovascular disease (CVD) compared with the general population. Prior studies have produced contradictory results on the association of dietary sodium intake with risk of CVD, and this relationship has not been investigated in patients with CKD.To evaluate the association between urinary sodium excretion and clinical CVD (...) events among patients with CKD.A prospective cohort study of patients with CKD from 7 locations in the United States enrolled in the Chronic Renal Insufficiency Cohort Study and followed up from May 2003 to March 2013.The cumulative mean of urinary sodium excretion from three 24-hour urinary measurements and calibrated to sex-specific mean 24-hour urinary creatinine excretion.A composite of CVD events defined as congestive heart failure, stroke, or myocardial infarction. Events were reported every 6

2016 JAMA

148. Role of Bile Acid Regulated Nuclear Receptor FXR and G Protein Coupled Receptor TGR5 in Regulation of Cardiorenal Syndrome (Cardiovascular Disease and Chronic Kidney Disease) Full Text available with Trip Pro

Role of Bile Acid Regulated Nuclear Receptor FXR and G Protein Coupled Receptor TGR5 in Regulation of Cardiorenal Syndrome (Cardiovascular Disease and Chronic Kidney Disease) 27045028 2018 01 16 2018 12 02 1524-4563 67 6 2016 06 Hypertension (Dallas, Tex. : 1979) Hypertension Role of Bile Acid-Regulated Nuclear Receptor FXR and G Protein-Coupled Receptor TGR5 in Regulation of Cardiorenal Syndrome (Cardiovascular Disease and Chronic Kidney Disease). 1080-4 10.1161/HYPERTENSIONAHA.115.06417 Levi (...) , Cytoplasmic and Nuclear 0 Receptors, G-Protein-Coupled 0C5V0MRU6P farnesoid X-activated receptor IM Animals Cardio-Renal Syndrome metabolism physiopathology therapy Diabetes Mellitus diagnosis metabolism Disease Progression Humans Lipid Metabolism drug effects Obesity diagnosis metabolism Prognosis Receptors, Cytoplasmic and Nuclear agonists physiology Receptors, G-Protein-Coupled agonists physiology 2016 4 6 6 0 2016 4 6 6 0 2018 1 18 6 0 ppublish 27045028 HYPERTENSIONAHA.115.06417 10.1161

2016 Hypertension (Dallas, Tex. : 1979)

149. Acute kidney injury and chronic kidney disease: from the laboratory to the clinic Full Text available with Trip Pro

chronic kidney disease appear to be less able to mount a complete 'adaptive' repair after acute insults, and instead repair maladaptively, with accelerated fibrosis and rates of renal functional decline. This article reviews the epidemiological studies in man that have demonstrated the links between these two processes. We also examine clinical and experimental research in areas of importance to both acute and chronic disease: acute and chronic renal injury to the vasculature, the pericyte (...) Acute kidney injury and chronic kidney disease: from the laboratory to the clinic Chronic kidney disease and acute kidney injury have traditionally been considered as separate entities with different etiologies. This view has changed in recent years, with chronic kidney disease recognized as a major risk factor for the development of new acute kidney injury, and acute kidney injury now accepted to lead to de novo or accelerated chronic and end stage kidney diseases. Patients with existing

2016 Nephrologie & therapeutique

150. Soluble Urokinase Receptor and Chronic Kidney Disease. Full Text available with Trip Pro

Soluble Urokinase Receptor and Chronic Kidney Disease. 26962914 2016 03 11 2018 12 02 1533-4406 374 9 2016 03 03 The New England journal of medicine N. Engl. J. Med. Soluble Urokinase Receptor and Chronic Kidney Disease. 891 10.1056/NEJMc1515787 Hayek Salim S SS Quyyumi Arshed A AA Reiser Jochen J eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Receptors, Urokinase Plasminogen Activator AIM IM N Engl J Med. 2015 Nov 12;373(20):1916-25 26539835 N Engl J Med. 2016 Mar 3;374(9 (...) ):890 26962915 N Engl J Med. 2016 Mar 3;374(9):890 26962916 Female Glomerular Filtration Rate Humans Kidney physiology Male Receptors, Urokinase Plasminogen Activator blood Renal Insufficiency, Chronic diagnosis 2016 3 11 6 0 2016 3 11 6 0 2016 3 12 6 0 ppublish 26962914 10.1056/NEJMc1515787 10.1056/NEJMc1515787#SA3

2016 NEJM

151. Soluble Urokinase Receptor and Chronic Kidney Disease. Full Text available with Trip Pro

Soluble Urokinase Receptor and Chronic Kidney Disease. 26962915 2016 03 11 2018 12 02 1533-4406 374 9 2016 03 03 The New England journal of medicine N. Engl. J. Med. Soluble Urokinase Receptor and Chronic Kidney Disease. 890 10.1056/NEJMc1515787 Quaglia Marco M University of Piemonte Orientale, Novara, Italy claudio.musetti@med.uniupo.it. Musetti Claudio C University of Piemonte Orientale, Novara, Italy claudio.musetti@med.uniupo.it. Cantaluppi Vincenzo V University of Piemonte Orientale (...) , Novara, Italy claudio.musetti@med.uniupo.it. eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Receptors, Urokinase Plasminogen Activator AIM IM N Engl J Med. 2015 Nov 12;373(20):1916-25 26539835 N Engl J Med. 2016 Mar 3;374(9):891 26962914 Female Glomerular Filtration Rate Humans Kidney physiology Male Receptors, Urokinase Plasminogen Activator blood Renal Insufficiency, Chronic diagnosis 2016 3 11 6 0 2016 3 11 6 0 2016 3 12 6 0 ppublish 26962915 10.1056/NEJMc1515787 10.1056

2016 NEJM

152. Soluble Urokinase Receptor and Chronic Kidney Disease. Full Text available with Trip Pro

Soluble Urokinase Receptor and Chronic Kidney Disease. 26962916 2016 03 11 2018 12 02 1533-4406 374 9 2016 03 03 The New England journal of medicine N. Engl. J. Med. Soluble Urokinase Receptor and Chronic Kidney Disease. 890 10.1056/NEJMc1515787 Schumacher Martin M University of Freiburg Medical Center, Freiburg, Germany ms@imbi.uni-freiburg.de. Wanner Christoph C Würzburg University Clinic, Würzburg, Germany. Beyersmann Jan J University of Ulm, Ulm, Germany. eng Letter Comment United States N (...) Engl J Med 0255562 0028-4793 0 Receptors, Urokinase Plasminogen Activator AIM IM N Engl J Med. 2015 Nov 12;373(20):1916-25 26539835 N Engl J Med. 2016 Mar 3;374(9):891 26962914 Female Glomerular Filtration Rate Humans Kidney physiology Male Receptors, Urokinase Plasminogen Activator blood Renal Insufficiency, Chronic diagnosis 2016 3 11 6 0 2016 3 11 6 0 2016 3 12 6 0 ppublish 26962916 10.1056/NEJMc1515787 10.1056/NEJMc1515787#SA2

2016 NEJM

153. Metabolically Healthy Obesity and Development of Chronic Kidney Disease: A Cohort Study. (Abstract)

subgroups.Chronic kidney disease was identified by a single measurement at each visit.Overweight and obesity are associated with an increased incidence of CKD in metabolically healthy young and middle-aged participants. These findings show that metabolically healthy obesity is not a harmless condition and that the obese phenotype, regardless of metabolic abnormalities, can adversely affect renal function.None. (...) Metabolically Healthy Obesity and Development of Chronic Kidney Disease: A Cohort Study. The risk for chronic kidney disease (CKD) among obese persons without obesity-related metabolic abnormalities, called metabolically healthy obesity, is largely unexplored.To investigate the risk for incident CKD across categories of body mass index in a large cohort of metabolically healthy men and women.Prospective cohort study.Kangbuk Samsung Health Study, Kangbuk Samsung Hospital, Seoul, South Korea.62

2016 Annals of Internal Medicine

154. Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronic kidney disease Full Text available with Trip Pro

Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronic kidney disease 27733948 2018 11 13 2147-9720 3 3 2016 Sep European journal of rheumatology Eur J Rheumatol Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronic kidney disease. 144-145 Oiwa Hiroshi H Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan. Mokuda Sho S (...) Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Department of Immunology, Hiroshima University School of Biomedical and Health, Hiroshima, Japan. eng Journal Article 2016 01 29 Turkey Eur J Rheumatol 101656068 2147-9720 Dr. Oiwa reports personal fees from Daiichi Sankyo, during the conduct of the study. 2015 07 02 2015 08 01 2016 10 14 6 0 2016 10 14 6 0 2016 10 14 6 1 ppublish 27733948 10.5152/eurjrheum.2015.0049 ejr-3-3-144 PMC5058456 Am J Kidney Dis. 2009 Jun

2016 European journal of rheumatology

155. The modifiers of chronic kidney disease in autosomal dominant polycystic kidney disease and the role of the endothelin-1 Full Text available with Trip Pro

The modifiers of chronic kidney disease in autosomal dominant polycystic kidney disease and the role of the endothelin-1 28197495 2019 01 09 2345-4202 5 1 2016 Journal of nephropharmacology J Nephropharmacol The modifiers of chronic kidney disease in autosomal dominant polycystic kidney disease and the role of the endothelin-1. 24-25 Einollahi Behzad B Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Lotfiazar Aidin A Nephrology and Urology (...) Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. eng Journal Article 2016 01 12 Iran J Nephropharmacol 101679372 2345-4202 Autosomal dominant polycystic kidney disease Chronic kidney disease Endothelin-1 2015 12 27 2016 01 10 2017 2 16 6 0 2017 2 16 6 0 2017 2 16 6 1 epublish 28197495 PMC5297502 Am J Kidney Dis. 1990 Nov;16(5):403-13 2239929 Iran J Kidney Dis. 2014 Jul;8(4):265-77 25001132 Lancet. 2007 Apr 14;369(9569):1287-301 17434405 J Am Soc Nephrol. 2013 May;24(6):1006

2016 Journal of nephropharmacology

156. Growth Monitoring for Children with Chronic Kidney Disease

). However the frequency of measurement we recommend provides significant benefits in our opinion but has a weak evidence base due to a general lack of studies in this area(1D). This guideline is endorsed by The British Society for Paediatric Endocrinology and Diabetes (BSPED), The British Association for Paediatric Nephrology (BAPN) and The Paediatric Renal Interest Nutrition Group (PRING). Stages of Chronic Kidney Disease (CKD) 14 Stage GFR* Description Management 1 > 90 Normal Renal Function (...) and anthropometric and nutritional measurements in children with mild to moderate renal insufficiency: a report of the Growth Failure in Children with Renal Diseases study. J Paediatr. 1990; 116: S46 – 54 2. Norman LJ, Coleman JE, MacDonald 1A, Thomsett AM, Watson AR: Nutrition and Growth in relation to severity of renal disease in children, Paediatric Nephrology 2000; 15, 259-65. 3. Kari JA, Gonzalez C, Lederman S, Shaw V, Rees L: Outcome and Growth of Infants with Severe Chronic Renal Failure. Kidney

2016 British Society for Paediatric Endocrinology and Diabetes

157. Systematic review with meta analysis: Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes

Systematic review with meta analysis: Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you (...) Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes Article Text Therapeutics/Prevention Systematic review with meta analysis Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes David W Johnson Statistics from Altmetric.com Commentary on: Cody JD , Hodson EM . Recombinant

2016 Evidence-Based Medicine

158. ERBP Guideline on Management of Older Patients with Chronic Kidney Disease Full Text available with Trip Pro

assessment 95% CI 95% Confidence Interval AKI Acute kidney injury CKD Chronic kidney disease CKD-EPI Chronic Kidney Disease Epidemiology Collaboration CM Conservative management eGFR Estimated glomerular filtration rate ERA-EDTA European Renal Association – European Dialysis and Transplant Association ERBP European Renal Best Practice ESKD End-stage kidney disease HD Hemodialysis HR Hazard ratio KFRE Kidney Failure Risk Equation MD Mean Difference MDRD Modification of Diet in Renal Disease OR Odds Ratio (...) PD Peritoneal dialysis QoL Quality of life RCT Randomized controlled trial REIN Renal Epidemiology and Information Network RR Relative Risk RRT Renal replacement therapy SGA Subjective global assessment 95% CI 95% Confidence Interval AKI Acute kidney injury CKD Chronic kidney disease CKD-EPI Chronic Kidney Disease Epidemiology Collaboration CM Conservative management eGFR Estimated glomerular filtration rate ERA-EDTA European Renal Association – European Dialysis and Transplant Association ERBP

2016 European Renal Best Practice

159. What Is the Significance of Elevated Troponin in Patients With Suspected Acute Coronary Syndrome and Chronic Kidney Disease?

. Cardiac troponin I and creatine kinase MB isoenzyme in patients with chronic renal failure. Nefrologia. 2012;32:809-818. 2. Kanderian AS, Francis GS. Cardiac troponins and chronic kidney disease. Kidney Int. 2006;69:1112-1114. 3. Michos ED, Wilson LM, Yeh HC, et al. Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome. Ann Intern Med.2014;161: 491-501. 4. Khan NA, Hemmelgarn BR, Tonelli M, et al. Prognostic value of troponin T and I (...) among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation. 2005;112:3088-3096. 5. Amsterdam EZ, Wenger NK, Peterson ED, et al. 2014 AHA/ACC guideline for the management of patients with non-ST- elevation acute coronary syndromes.JAm Coll Cardiol. 2014;64:e139-228. 6. Acharji S, Baber U, Mehran R, et al. Prognostic signi?cance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney Systematic Review Snapshot 108 Annals of Emergency

2016 Annals of Emergency Medicine Systematic Review Snapshots

160. Racial disparities in chronic kidney diseases in the United States; a pressing public health challenge with social, behavioral and medical causes Full Text available with Trip Pro

on Ethnicity, Culture and Health, School of Public Health, University of Michigan, Ann Arbor, MI, USA. eng R01 AG018418 AG NIA NIH HHS United States Editorial 2015 12 12 Iran J Nephropharmacol 101679372 2345-4202 Chronic kidney disease End stage renal disease Health disparities Socio-economics 2015 10 07 2015 12 05 2017 2 16 6 0 2015 12 12 0 0 2015 12 12 0 1 epublish 28197489 PMC5297505 Am J Mens Health. 2013 Jul;7(4 Suppl):58S-67S 23609347 J Diabetes Complications. 2003 Jan-Feb;17(1):39-58 12505756 Clin J (...) Racial disparities in chronic kidney diseases in the United States; a pressing public health challenge with social, behavioral and medical causes 28197489 2018 11 13 2345-4202 5 1 2016 Journal of nephropharmacology J Nephropharmacol Racial disparities in chronic kidney diseases in the United States; a pressing public health challenge with social, behavioral and medical causes. 4-6 Assari Shervin S Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA ; Center for Research

2015 Journal of nephropharmacology